Five Costly Planning Mistakes in Gene Therapy

A gene therapy plan does not fail because the science is weak. It fails because the business case around the science is modelled like the wrong kind of company. Before the cost tables and market data below, here are the five errors that most often sink a raise for first-time founders in this field.

• Modelling revenue like a device company. A one-time cure is not a razor-and-blades product. There is no recurring per-patient revenue, no subscription, and no obvious refill. Your model should treat each patient as a single high-value event, with revenue that is lumpy, front-loaded, and heavily dependent on payer contracts. Investors who back this sector will notice immediately if your forecast smooths revenue like a SaaS curve.
• Underbudgeting GMP manufacturing. Founders routinely price a viral-vector batch at a fraction of the real figure. A single good-manufacturing-practice batch from a contract manufacturer commonly runs $1M to $5M, and CDMO capacity must be booked many months ahead. Leaving manufacturing as a line item to "figure out later" is the fastest way to lose credibility with a technical investor.
• Forgetting the 15-year follow-up. The FDA mandates long-term follow-up of up to 15 years for viral-vector products. That is a real, ongoing cost that lives in your operating model long after your first dose. Plans that end their cost projection at approval look naive to anyone who has run a biologics program.
• Pitching a single indication with no platform. A single-program company is a single point of failure. The plans that raise well show how one validated vector, capsid, or delivery platform opens a pipeline of two, three, or four indications. That is what turns a science project into an investable franchise.
• Building a facility too early. An in-house GMP suite can cost $40M or more. Committing to it before you have multiple programs and predictable volume ties up capital you should be spending on data. Most successful early-stage developers stay CDMO-first and only internalise manufacturing once the pipeline justifies it.

Each of these mistakes is a modelling decision, not a scientific one, which is exactly why a purpose-built plan matters. Our bespoke business plan service builds the financial model around these realities rather than a generic startup template.

What It Costs to Reach a Trial

There is no single "startup cost" for a gene therapy business, because the number depends entirely on how far you intend to take the asset yourself. A founder who wants to reach a first-in-human trial and then out-license needs a very different budget from one who plans to carry a therapy through to commercial launch. The full clinical-stage cost of bringing one cell or gene therapy to market has been estimated at roughly $1.94 billion per approved product (Pharmaceutical Medicine, Springer, 2023). Almost no founder funds that alone; the practical planning question is how much you need to reach the next value-inflection point.

For a single-program venture that outsources manufacturing, a realistic budget to a first-in-human trial sits between $2.5M and $10M, with roughly $20M needed to reach a Phase 1/2 data readout. Building your own manufacturing pushes the figure past $40M before you dose a single patient. In the UK, comparable programs run around £1.8M to £30M-plus depending on the same choices.

Cost Breakdown (Outsourced-Manufacturing Model)

• Preclinical program: $2M–$8M (£1.5M–£6M): vector and capsid design, potency assays, and the IND-enabling toxicology package.
• GMP viral-vector batch (per run): $1M–$5M (£0.8M–£4M): booked with a CDMO such as Charles River, Resilience, or AGC Biologics.
• Phase 1 clinical trial: $4M–$15M (£3M–£12M): sites, patient recruitment for a rare indication, and long-term monitoring setup.
• Regulatory and quality infrastructure: $0.5M–$3M (£0.4M–£2.5M): IND/CTA preparation, a qualified person (QP) or equivalent, and pharmacovigilance systems.
• Working capital (12–18 months burn): often the largest single line, driven by a scientific team of PhD-level staff.
• Own GMP facility (optional, later): $40M+ (£30M+): only sensible with a multi-program pipeline.

How Founders Fund It

Gene therapy is capital-intensive and pre-revenue for years, so the funding sequence matters as much as the total. Most founders raise in tranches tied to milestones: a seed round to fund IND-enabling studies, a Series A once safety and early efficacy signals land, and later rounds or a partnership once a Phase 1/2 readout de-risks the asset. Non-dilutive sources matter too. In the US, agencies such as the National Institutes of Health and BARDA fund translational work; in the UK, Innovate UK and the Cell and Gene Therapy Catapult support platform development. Real early rounds are visible in the market: Danish start-up Fuse Vectors raised a $5.2M pre-seed for its vector technology, and Tetraneuron secured over €3.5M in non-dilutive funding (Labiotech, 2025). Our funding-ready plans map each raise to the specific data milestone it unlocks, which is what a life-sciences investor expects to see.

Three Business Models Compared

"Gene therapy business" describes at least three very different companies, and the model you choose reshapes your entire plan: capital needs, headcount, risk profile, and exit. The strongest plans commit to one primary model and are explicit about why. Here is how the three compare.

Most first-time founders start as either an integrated developer of a single asset or a platform-licensing company, because the CDMO route demands facility capital before any revenue. The plan should state your model in the first page of the executive summary. An investor reading a "platform" pitch that is secretly asking for facility money will pass. For a related deep-tech path, our market research and content service can also support a stem cell therapy or genomics venture where the model choice is just as pivotal.

The One-Line Pitch Test

A useful discipline before writing the full plan is to compress the business into a single fundable sentence, because if it cannot survive that compression it is not ready for an investor's inbox. The structure that works in this field is roughly: "We are developing a [vector type] therapy for [indication with named patient population], built on [owned or licensed platform], seeking [amount] to reach [specific data milestone] within [timeframe], with a pipeline of [number] further indications." Filling that in forces every weak assumption to the surface. If you cannot name the indication precisely, quantify the population, or attach the raise to a concrete milestone, the gaps are visible immediately, which is exactly why a scientific investor asks for it in the first meeting.

Regulatory Path: IND to Approval

Regulation is not a compliance footnote in gene therapy; it is the spine of the business plan, because each regulatory milestone is also a fundraising and valuation event. Advanced therapy products are among the most heavily scrutinised categories anywhere in medicine, and the plan needs to show you understand the sequence in each jurisdiction you intend to operate in.

United States (FDA)

Gene therapies are regulated by the Center for Biologics Evaluation and Research (CBER). The core sequence:

• Investigational New Drug (IND) application: required before any human trial. The FDA has a 30-day review clock; if it does not place a clinical hold, the trial can proceed. Preparing an IND-ready package commonly costs $1M–$3M in studies and filing.
• Phase 1–3 clinical trials: often smaller than conventional drug trials for rare indications, but with intensive safety monitoring.
• Biologics License Application (BLA): the marketing submission, with a 180-day review plus up to 90 days of comment. The FY2025 PDUFA program fee is roughly $4.3M.
• Long-term follow-up (LTFU): up to 15 years for viral-vector products, a cost that persists after launch (FDA, 2025).

Expedited routes matter to the timeline and the story: RMAT (Regenerative Medicine Advanced Therapy) designation, Breakthrough Therapy, and Priority Review can each compress the path. A plan that names the designation it will pursue signals sophistication.

United Kingdom (MHRA)

Since Brexit, the Medicines and Healthcare products Regulatory Agency reviews UK clinical trials and marketing authorisations independently of the EMA. A Clinical Trial Authorisation (CTA) is required to begin a trial; as of late 2024 the MHRA was clearing CTAs in an average of about 49 days against a 60-day statutory target (Cell and Gene Therapy Catapult, 2024). The MHRA's Innovative Licensing and Access Pathway (ILAP) and the PRIME-style support can shorten time to authorisation by roughly a year. Handling genetically modified organisms and human tissue also brings the Human Tissue Authority and the Health and Safety Executive into scope.

European Union (EMA)

In the EU, gene therapies are advanced therapy medicinal products (ATMPs) under Regulation (EC) No 1394/2007. Marketing authorisation is centralised through the European Medicines Agency, with the Committee for Advanced Therapies (CAT) leading the scientific assessment. A Clinical Trial Application triggers a 60-day review. For a UK or US founder, the EU is usually a phase-two market entered after a home-market authorisation, but naming it early shows investors you see the full addressable market.

Revenue, Pricing & Margins

Gene therapy has the most unusual revenue profile in medicine: a single administration can cure a disease, and it is priced accordingly. Approved one-time therapies carry list prices from about $2.1M to $4.25M per patient. Zolgensma (Novartis) lists at $2.125M, Casgevy (Vertex and CRISPR Therapeutics) at $2.2M, Hemgenix (CSL Behring and uniQure) and Beqvez (Pfizer) near $3.5M, and Lenmeldy (Orchard Therapeutics) at roughly $4.25M (IntuitionLabs, 2025). These are the highest unit prices in the pharmaceutical industry, and they exist because the therapy replaces a lifetime of chronic treatment.

The Pre-Revenue Problem

The hard truth your plan must confront is that product revenue only arrives after approval, which is years away. In the meantime, a gene therapy company funds itself through out-licensing deals, research collaborations, milestone payments, platform-technology licences, and non-dilutive grants. Modelling this bridge is the difference between a fundable plan and a science pitch.

Worked Example

Consider a single-program AAV venture with a monthly burn of $650,000, running a 15-patient Phase 1/2. Reaching a data readout takes about 30 months, so the program costs roughly $20M to that inflection point. With clean safety and early efficacy data, the founders license the asset to a Tier-1 pharma partner for a $30M–$75M upfront payment plus development and sales milestones and a mid-single-digit to low-double-digit royalty. That single deal both returns capital to seed investors and validates the platform for the next indication. Note that even for an eventual product, gross margins on the manufactured biologic run a healthy 60–80% ex-CDMO, but that margin only ever appears post-approval. A plan that shows this bridge, rather than a straight product-revenue curve, is what raises money.

Reimbursement Is Part of the Revenue Model

Because no payer can absorb a $3M cost as a single line, the reimbursement structure is not a footnote; it is central to whether the price on your model is real. Three approaches now dominate. Outcomes-based agreements tie payment to whether the therapy actually works over a defined period, with rebates if it does not. Instalment or annuity models spread the cost over several years, better matching the lifetime value of a cure. And risk pools or specialist funds, such as the arrangements England's National Health Service has used for the first approved gene therapies, share the budget impact across a larger population. A credible financial model should pick a primary reimbursement mechanism per market and stress-test the price against it, rather than assuming full list price on every patient. Investors have watched approved therapies struggle commercially despite scientific success precisely because the reimbursement path was underdeveloped, so demonstrating command of it is a genuine differentiator.

Market Size & Growth

The global gene therapy market was valued at approximately $11.07 billion in 2025 and is projected to reach $63.52 billion by 2035, a compound annual growth rate of about 19.09% (Precedence Research, 2025). Estimates vary by scope: Mordor Intelligence puts the 2025 market near $7.95B growing at roughly 20.86% (Mordor Intelligence, 2025), while the broader cell-and-gene-therapy category is forecast to exceed $47B by 2035. The spread reflects different definitions, but every credible source agrees on the direction: near 20% annual growth for the next decade.

Growth is driven by a widening pipeline. Sickle cell disease, haemophilia, spinal muscular atrophy, inherited retinal disorders, and metachromatic leukodystrophy already have approved therapies, and the addressable list of monogenic diseases runs into the thousands. The UK is a genuine hub rather than a spectator: the Stevenage and Oxford-Cambridge clusters, the Cell and Gene Therapy Catapult, and a supportive MHRA make Britain one of the more attractive places outside the US to base a program. That geography is worth naming in your plan, because it shapes talent access, grant eligibility, and manufacturing partners.

Two structural forces sit behind the headline growth rate. The first is scientific: the toolkit has matured. AAV capsid engineering, lentiviral manufacturing, and CRISPR-based editing have moved from academic curiosities to reproducible platforms, which lowers the technical risk of each new program even as the science stays hard. The second is commercial: payers and health systems are slowly building the reimbursement machinery to pay millions per dose, through outcomes-based agreements and instalment models. When the National Health Service in England agreed access deals for the first sickle cell gene therapies, it signalled to founders that a UK launch is a real commercial endpoint, not a theoretical one. A plan that references how it will engage payers, health-technology assessment bodies such as NICE, and specialist commissioning is far more convincing than one that assumes list price times patient count.

The counterweight to all of this is concentration. A relatively small number of large pharmaceutical companies and specialist funds control most of the capital and most of the acquisition activity, which means the realistic exit for many founders is a licensing deal or an acquisition rather than an independent commercial launch. That is not a weakness in a plan; it is the base case. Naming plausible acquirers, describing the partnership structures that are common in the field, and showing which data milestone makes the company attractive to them is exactly the kind of commercial realism that separates a fundable plan from a wish list.

One number anchors this whole section and it is easy to get wrong: the addressable patient population. Because most gene therapies target rare diseases, the population is small, precise, and knowable, often a few hundred to a few thousand patients per year in a given market. That is a strength, not a weakness, when the price is measured in millions per dose; a therapy treating 2,000 eligible patients a year at $2.5M each addresses a $5 billion annual opportunity. But the figure has to be built bottom-up from epidemiology, diagnosis rates, and the fraction of patients who are actually eligible and reachable, not top-down from a market-report headline. A plan that derives its addressable population credibly, and then applies a realistic penetration curve over several years, earns trust that a plan quoting a trillion-dollar healthcare number never will.

A Realistic Launch Timeline

Gene therapy timelines are long, and pretending otherwise is a fast way to lose credibility. A plan that shows a candid, milestone-by-milestone path, with the fundraising events attached to each, reads as far more serious than one promising an implausible sprint to market. The sequence below reflects a CDMO-first, single-lead-program venture; your own timeline will vary with indication and capital.

• Months 0-6: Company formation and licence. Incorporate, execute the IP licence or assignment, assemble the founding scientific and regulatory team, and close a seed round to fund the work below.
• Months 6-18: IND-enabling studies. Optimise the vector, run potency and biodistribution assays, and complete the toxicology package. Book CDMO capacity for the first GMP batch during this window, because slots are scarce.
• Months 12-24: First GMP batch and regulatory submission. Manufacture clinical-grade material and prepare the IND (US) or CTA (UK). Regulatory pre-submission meetings de-risk the filing and are worth the time.
• Months 24-30: Trial start. Open sites, secure ethics approval, and dose the first patient. This first-in-human milestone is the single biggest value-inflection point and typically the moment a Series A closes.
• Months 30-48: Phase 1/2 readout. Generate safety and early efficacy data. A clean readout is what triggers a partnership, a larger raise, or the decision to carry the asset further.
• Years 4-8: Pivotal trial, submission, and approval. For founders taking the asset to market, a pivotal study, BLA or MAA submission, and long-term follow-up commitments fill the remaining years.

The practical lesson for the financial model is that cash must be planned in overlapping tranches, not one lump sum. Each raise buys the company to the next milestone that makes the following raise cheaper. A plan that shows this staircase, with realistic gaps between rounds and a buffer for delay, is what a life-sciences investor is looking for.

Team, Operations & the Diligence Bar

In most industries a business plan can lead with the product. In gene therapy, investors read the team section first, because the field is defined by execution risk. The people who can move an asset from a licensed patent to a cleared trial are rare, and a plan that does not evidence that capability will not clear diligence regardless of how strong the science looks on paper.

The Roles Investors Expect to See

• Chief Scientific Officer: a translational scientist with hands-on experience taking a vector or platform toward the clinic, not only bench research.
• Regulatory and quality lead: someone who has actually authored an IND or CTA and understands GMP and the qualified-person function. This is often the first senior hire after the founders.
• Clinical and medical leadership: a medical director or clinical adviser with rare-disease trial experience, which matters enormously for patient recruitment in small populations.
• Manufacturing and process lead: the person who manages the CDMO relationship, tech transfer, and batch scheduling. Manufacturing failures, not scientific ones, delay many programs.
• Scientific advisory board: named clinical and academic advisers whose credibility de-risks the story for investors who cannot assess the science themselves.

Operations the Plan Must Address

Beyond the team, the operations section should demonstrate command of the things that actually derail advanced-therapy companies. Chief among them is the manufacturing supply chain: viral-vector production is labour-intensive, requires multiple purification steps, and has to pass potency, purity, and safety testing before any batch reaches a patient (Charles River, 2025). A single failed batch can cost months and a seven-figure sum, so the plan should name the CDMO relationship, the batch schedule, and the contingency if a run fails.

The plan should also address patient recruitment, which for a rare monogenic disease can mean identifying a few dozen eligible patients across an entire country. Partnerships with patient advocacy groups and specialist treatment centres are not soft touches here; they are the operational backbone of the trial. Finally, the cold-chain and administration logistics, particularly for ex-vivo therapies where a patient's cells are shipped, modified, and returned, belong in the operations narrative rather than being waved away. Investors who have been burned before look specifically for founders who understand that in this field, logistics and manufacturing are where value is created or destroyed.

Key Terms Investors Expect You to Use Correctly

A gene therapy plan is read by scientific investors and their advisers. Using the vocabulary precisely is a low-cost signal of competence; using it loosely is an equally cheap signal that you are not ready. These are the terms that recur in almost every diligence conversation.

• AAV (adeno-associated virus): the most common delivery vector for in-vivo gene therapy. Non-integrating and relatively safe, but limited in the size of genetic payload it can carry. Zolgensma and several eye therapies use AAV.
• Lentiviral vector: an integrating vector used mostly for ex-vivo work, where cells are modified outside the body and returned. Higher payload capacity than AAV.
• CRISPR/Cas9: a gene-editing tool rather than a delivery vector. Casgevy was the first CRISPR-edited medicine approved anywhere in the world.
• In-vivo vs ex-vivo: in-vivo delivers the therapy directly into the patient; ex-vivo edits cells outside the body first. The distinction drives your entire manufacturing and logistics model.
• CDMO: contract development and manufacturing organisation. The partner most early-stage developers rely on for GMP vector production instead of building a facility.
• GMP: good manufacturing practice, the quality standard your product batches must meet to be used in humans.
• ATMP: advanced therapy medicinal product, the EU and UK regulatory category that covers gene, cell, and tissue-engineered therapies.
• Vector shedding: the release of vector from a treated patient, a safety and long-term-follow-up consideration regulators scrutinise closely.

More Founder Questions

These are the questions people searching around gene therapy as a business most often ask, answered without the jargon.

Is gene therapy profitable?

At the company level, most gene therapy developers are loss-making for years and reach profitability only after a product launches or a large partnership lands. At the product level, an approved therapy can be extraordinarily profitable, with gross margins of 60–80% on a product that lists in the millions per dose. The plan's job is to bridge those two truths: how the business survives the loss-making years to reach the profitable product.

What is the difference between cell therapy and gene therapy as a business?

Gene therapy alters or adds genetic material, usually delivered by a vector, and scales more like a manufactured biologic. Cell therapy modifies living cells, often the patient's own, and depends on complex per-patient logistics that scale closer to a service. Autologous cell therapy has a cost-of-goods and supply-chain profile that a gene therapy plan does not, which is why the two should never be planned with the same financial template.

Do I need a scientific co-founder or advisory board?

For fundraising, effectively yes. Investors in this sector back teams with demonstrated translational and regulatory experience. A credible plan names a chief scientific officer or a scientific advisory board with relevant clinical and manufacturing track records. If you are a business founder with a licensed asset, building that bench is part of the plan, not an afterthought.

Can I license a therapy from a university instead of inventing one?

Yes, and it is one of the most common routes. Many gene therapy companies are academic spin-outs built around a licensed patent or a specific vector from a university tech-transfer office. The plan then centres on translating that licence into a fundable clinical program, which is exactly the situation in the case study below.

Sample Business Plan Preview

Here is an extract from a gene therapy business plan written by our team, so you can see the level of specificity a life-sciences investor expects:

What's in the Template

Every Avvale business plan template is pre-structured for its industry. The gene therapy version is built around the sections a scientific investor and a grant committee actually read:

• Executive Summary: Your asset, indication, model, and the raise, framed to hold a life-sciences investor in the first 60 seconds.
• Scientific & IP Overview: The vector or platform, the licensed or owned intellectual property, and the freedom-to-operate position.
• Indication & Market Analysis: Addressable patient population, standard of care, and the unmet need your therapy fills.
• Regulatory Strategy: The IND/CTA-to-approval path, target designations (RMAT, ILAP), and the milestone timeline.
• Manufacturing Plan: CDMO-first or in-house rationale, batch economics, and the scale-up story.
• Development Plan & Milestones: Preclinical to clinical roadmap with the data readouts that unlock each raise.
• Team & Advisory Board: Scientific, clinical, and regulatory credibility, which this sector weights heavily.
• Financial Model: Milestone-based revenue, staged funding, burn rate, and the licensing or launch scenario.

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a multi-year model with burn projection, staged-funding scenarios, milestone-triggered revenue, break-even analysis, and the capital-requirements schedule investors expect from an advanced-therapy company.

Frequently Asked Questions